Ticker: MRK

Merck

Pharma Healthcare Drug Manufacturers - General

Price 141.08

Reco Hold Potential 73 Risk 43 Updated 2026-10-27

Official website

Forecast impact

positive

Target +28.0% target fill 78.1%

Reaction D5 pending · D10 pending fresh confirmed · market trust

Impact Potential +6 · Risk -3 valid until 2026-11-25

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Merck & Co., Inc. is a global healthcare company that develops and manufactures pharmaceuticals, vaccines, biologics, and animal health products. Its core products include treatments for cancer, diabetes, and infectious diseases, with significant revenue generated from its oncology and vaccine segments. The company also focuses on research and development to innovate new therapies and improve existing ones.

Investment Profile

The stock presents a balanced investment profile, appealing to investors seeking a combination of growth and income through dividends. With a moderate dividend yield and a focus on innovation, it may attract those interested in stable returns while also considering potential capital appreciation.

Category: Pharma Sector: Healthcare Industry: Drug Manufacturers - General Investment style: Growth Horizon: Long-term Company type: Blue Chip Company type: Market Leader Experience: Basic

Fundamental metrics (experimental) Updated: 2026-10-26

EPS (TTM) — earnings per share for the last 12 months, $: 1.26
Revenue QoQ — quarter-over-quarter revenue growth: 2.0%
EPS surprise: 51.9%
20d volatility: 1.8%
Dividend yield: 2.3%
last ex-date: 2026-09-15

AI recommendation changes

Date	Before	After	Reason
2026-10-25	Buy	Hold	Solid fundamentals, but mixed momentum signals present risks.
2026-06-27	Hold	Buy	Strong momentum and solid fundamentals support growth potential.
2026-06-19	Buy	Hold	Weak momentum and fundamentals suggest caution.
2026-06-09	Hold	Buy	Stable dividend, moderate growth, cautious market sentiment.
2026-06-01	Buy	Hold	Solid dividend yield, but mixed momentum signals.
2026-05-24	Hold	Buy	Strong momentum and solid dividend yield support growth.
2026-05-08	—	Hold	Mixed performance; cautious outlook amid market volatility.
2026-05-05	Hold	Buy	Компания Merck демонстрирует сильный рост за последние 120 дней и стабильную дивидендную доходность. Несмотря на недавние колебания доходов, потенциал для роста остается высоким благодаря инновациям в области здравоохран
2026-04-27	Buy	Hold	Компания Merck демонстрирует стабильный рост в долгосрочной перспективе, однако недавние колебания цен и снижение выручки указывают на определенные риски в краткосрочной перспективе.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-10-26	Barclays	Target Raised	150 → 180	145.27
2026-10-22	Wells Fargo	Update	— → 165	147.24
2026-10-19	Goldman Sachs	Target Lowered	160 → 155	146.265
2026-10-12	RBC Capital	Target Lowered	— → 145	145.6
2026-10-08	Cantor Fitzgerald	Target Raised	— → 145	142.79
2026-09-29	Scotiabank	Target Raised	155 → 180	147.15
2026-09-11	Berenberg Bank	Target Raised	— → 137	144.71
2026-09-10	HSBC	Target Raised	150 → 172	147.6
2026-09-09	Leerink Partners	Target Raised	127 → 161	148.49
2026-09-08	Guggenheim	Target Raised	— → 170	150.34
2026-09-04	Wells Fargo	Target Raised	150 → 170	152.34
2026-08-25	Argus Research	Target Raised	145 → 170	153.61
2026-08-25	Wolfe Research	Target Raised	155 → 180	150.69
2026-08-21	Goldman Sachs	Target Raised	140 → 160	149.25
2026-08-20	BMO Capital	Target Raised	142 → 170	149.64999
2026-08-20	UBS	Target Raised	145 → 175	152.22
2026-08-20	RBC Capital	Rating Downgraded	— → 150	152.22
2026-08-20	UBS	Update	— → 150	152.22
2026-08-19	Morgan Stanley	Rating Upgraded	— → 179	152.22
2026-08-12	Daiwa	Update	— → 143	130.45
2026-08-11	Argus Research	Target Raised	— → 145	130.9
2026-08-05	Morgan Stanley	Target Raised	113 → 116	130.39999
2026-08-05	Guggenheim	Target Raised	145 → 146	128.04
2026-07-29	Barclays	Target Raised	140 → 150	131.835
2026-07-27	Bernstein	Target Raised	— → 105	132.34
2026-07-13	BMO Capital	Target Raised	— → 142	124.08
2026-07-13	Guggenheim	Target Raised	— → 145	123.54
2026-07-06	HSBC	Target Raised	135 → 150	126.05
2026-06-30	Jefferies	Target Raised	— → 141	129.38
2026-06-29	Scotiabank	Target Raised	136 → 155	129.38
2026-06-02	Guggenheim	Update	— → 140	115.21
2026-05-01	Morgan Stanley	Target Raised	109 → 112	112.47
2026-03-12	Wells Fargo	Target Raised	— → 150	116.22
2026-02-24	RBC Capital	Update	— → 142	123.93
2026-02-13	Deutsche Bank	Rating Upgraded	— → 150	121.53
2026-02-04	Goldman Sachs	Target Raised	120 → 133	115.86
2026-02-04	BMO Capital	Target Raised	130 → 135	115.86
2026-02-04	Bernstein	Target Raised	95 → 100	115.86
2026-02-03	Scotiabank	Target Raised	120 → 136	116.37
2026-01-27	Cantor Fitzgerald	Target Raised	83 → 116	107.4
2026-01-08	Wolfe Research	Rating Upgraded	— → 135	108.59

News Page 1 of 2

Doctors Highlight Major Advancement in Melanoma Treatment from Moderna (MRNA) and Merck (MRK) Cancer Vaccine Data

10/23/2026, 09:38 AM business research healthcare Merck Moderna

The recent Phase 3 trial results for Moderna and Merck's personalized cancer vaccine indicate a significant advancement in melanoma treatment, despite a sharp stock sell-off that reflects investor skepticism about its commercial viability. Oncologists view the data as a potential breakthrough that could reshape standard care for melanoma patients post-surgery.

Moderna (MRNA) shares drop 25% following leak of partial cancer vaccine data

10/22/2026, 11:38 AM business stock_drop healthcare Merck Moderna

Moderna's stock experienced a significant decline of up to 25% following a leak of incomplete data regarding its cancer vaccine, despite later positive full data results that met Wall Street expectations.

Merck CEO Rob Davis anticipates faster production timeline for breakthrough cancer vaccine developed with Moderna

10/14/2026, 10:38 AM business announcement healthcare Merck Moderna

Merck's CEO Rob Davis anticipates that the manufacturing timeline for its personalized cancer vaccine, developed in partnership with Moderna, will shorten over time, potentially increasing patient access. This development is crucial as it aligns with Merck's strategy to maintain revenue streams amid the impending loss of exclusivity for its leading drug, Keytruda.

Analysts Ritholtz Wealth Management highlight Merck & Co., Inc. (MRK) and Amgen (AMGN) as biotech stocks show significant breakout potential

08/24/2026, 08:38 AM investing review Analysts: analysts, Ritholtz biotech Merck Amgen

Merck's recent Phase 3 trial success in combination therapy has significantly boosted its stock, indicating a positive shift in investor sentiment towards its pipeline. This development, along with Amgen's strong performance, highlights a broader resurgence in the biotech sector, which could attract more investor interest.

S&P 500 Experiences Weekly Loss Despite Surge in Overbought Stocks Including Moderna and Merck

08/22/2026, 05:31 AM investing review Estee Lauder Merck Agilent Technologies Thermo Fisher Scientific Moderna

The S&P 500 experienced a decline after three weeks of gains, primarily due to rising Treasury yields, while several individual stocks, particularly in the healthcare and cosmetics sectors, reached overbought levels following strong earnings and positive trial results.

U.S. Treasury Secretary Scott Bessent Addresses Economic Pressure on Iran Amid Bond Market Challenges

08/20/2026, 06:36 PM review finance Merck Walmart Moderna

U.S. Treasury Secretary Scott Bessent's recent comments on economic strategies regarding Iran and the U.S. budget deficit have failed to stabilize bond yields, leading to a decline in the S&P 500. This situation raises concerns about the effectiveness of government interventions in the current market environment.

Analysts Morgan Stanley upgraded Merck & Co. (MRK) to Overweight and raised target price to $179, citing strong cancer drug pipeline

08/20/2026, 05:37 AM investing rating_growth Analysts: analysts, Morgan Stanley healthcare Merck

Morgan Stanley has upgraded Merck's stock to overweight, citing confidence in its drug pipeline to sustain growth despite the impending expiration of the Keytruda patent in 2028. The firm raised its price target for Merck shares to $179, indicating a potential 17% upside.

U.S. Treasury Department Doubles Bond Purchases to Manage Rising Debt Exceeding $40 Trillion

08/19/2026, 06:36 PM announcement finance Nvidia Merck Moderna

The U.S. Treasury's decision to double its bond purchases aims to lower borrowing costs amid a surging national debt, which has now exceeded $40 trillion. This move is significant as it impacts both bond yields and stock market performance, while raising concerns about long-term fiscal sustainability.

Stocks Making Significant Midday Moves: Moderna Surges 120%, Pilgrim’s Pride Rallies 15%, Target Gains 5%

08/19/2026, 09:37 AM business review Pilgrim's Pride La-Z-Boy Marvell Technology Lowe's Companies Merck CoStar Group Alexandria Real Estate Coinbase Target Moderna

Midday trading saw significant stock movements, particularly for Moderna and Merck, following positive trial results for a cancer vaccine, while other companies like Pilgrim's Pride and Target also experienced notable gains.

Stocks to Watch: Moderna and Merck Surge on Positive Cancer Vaccine Trial Results, While Lowe’s and La-Z-Boy Face Declines

08/19/2026, 05:36 AM business review Mercury Systems La-Z-Boy Estee Lauder Lowe's Companies Analog Devices Toll Brothers Keysight Technologies Merck Moderna

Moderna and Merck's shares surged following positive results from a late-stage trial of their personalized cancer vaccine, while other companies like Keysight Technologies and Estee Lauder reported strong earnings, impacting their stock prices positively. Conversely, Lowe's and La-Z-Boy faced declines due to disappointing forecasts and earnings results.